Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recamtruzumab
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Recamtruzumab (also known as SHR-A1811) is a next-generation antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). Developed by Jiangsu Hengrui Pharmaceuticals, it consists of a humanized anti-HER2 monoclonal antibody (trastuzumab) covalently linked to a potent topoisomerase I inhibitor payload, rezetecan (an exatecan derivative), via a protease-cleavable linker. The drug is designed to treat HER2-expressing or HER2-mutated solid tumors, particularly breast cancer, by binding to HER2 on the cell surface, undergoing internalization, and releasing the cytotoxic payload to induce DNA damage and apoptosis. It features a high drug-to-antibody ratio (DAR) of approximately 8 and exhibits a bystander killing effect, which enhances its efficacy in tumors with heterogeneous HER2 expression.
- Other names
- trastuzumab rezetecan
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on recamtruzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recamtruzumab.